头孢替安在内科的临床评估
[Clinical evaluation of cefotiam in internal medicine].
作者信息
Kawamura S, Sakata Y, Chiba Y, Yoshida Y, Aizawa M, Nara H, Yanagiya S, Fukushi K, Ohmi T, Okamoto K, Komatsu Y, Haneda Y, Tanabe K, Segawa M, Yamagata A, Kawatsu S
出版信息
Jpn J Antibiot. 1982 May;35(5):1136-44.
Cefotiam (CTM) was administered to 52 patients with infectious disease associated with respiratory system, hematological malignancy, urinary system and other system. Good clinical responses were obtained in 38 out of 52 cases (73.1%). Neither objective and subjective side effects nor extreme abnormalities of laboratory tests were observed in these patients. It can be, therefore, concluded that CTM is 1 of the most useful drugs for infectious diseases in respiratory system, hematological malignancy, urinary system and other system.
对52例患有呼吸系统、血液系统恶性肿瘤、泌尿系统及其他系统相关传染病的患者给予头孢替安（CTM）治疗。52例患者中有38例（73.1%）获得了良好的临床反应。这些患者未观察到客观和主观副作用，实验室检查也未出现极端异常情况。因此，可以得出结论，头孢替安是治疗呼吸系统、血液系统恶性肿瘤、泌尿系统及其他系统传染病最有效的药物之一。
Zotero 插件